An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors

An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors soansm01 Wed, 04/22/2026 - 05:02 Marstacimab (PF-06741086) Marstacimab (PF-06741086) PHASE III Mon, 03/09/2020 - 12:00 Tue, 04/29/2025 - 12:00 NCT03938792 B7841005 Final Public Disclosure Synopsis .pdf (126.25 KB) N https://clinicaltrials.gov/study/NCT05145127?term=B7841005&viewType=Card&rank=1 B7841005